T. Garay

发表

Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo

A. Czirók, C. Pirker, W. Berger, 2018, Clinical Cancer Research.

Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.

B. Ghanim, C. Pirker, W. Berger, 2014, American journal of respiratory and critical care medicine.

CELL BIOLOGY AND SIGNALING

V. P. Collins, Michael A. Koldobskiy, R. Spang, 2010 .

The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma

W. Berger, I. Waizenegger, W. Klepetko, 2018, Journal of Molecular Medicine.

Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase

S. Pleschka, M. Stukova, M. Bergmann, 2017, Molecular therapy oncolytics.

Cell type-dependent HIF1 α-mediated effects of hypoxia on proliferation, migration and metastatic potential of human tumor cells

G. Szakács, B. Hegedűs, I. Kenessey, 2017, Oncotarget.

The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb

J. Tímár, I. Varga, B. Hegedűs, 2019, International journal of molecular sciences.

Epigenetic down‐regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma

B. Ghanim, C. Pirker, W. Berger, 2015, The Journal of pathology.

Nintedanib and Dasatinib Treatments Induce Protective Autophagy as a Potential Resistance Mechanism in MPM Cells

Julian N. Heidenreich, A. Czirók, S. Peña-Llopis, 2022, Frontiers in Cell and Developmental Biology.

Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca2+ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK

J. Tímár, Rita Padányi, Á. Enyedi, 2017, Front. Oncol..

Selective Inhibition of HIF1α Expression by ZnSO4 Has Antitumoral Effects in Human Melanoma

E. Raso, J. Tímár, A. Ladányi, 2019, Pathology & Oncology Research.

ONCOGENE DEPENDENT REGULATION OF MIGRATION AND PROLIFERATION IN HUMAN TUMOR CELLS

T. Garay, 2013 .

Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells

W. Berger, B. Döme, J. Tímár, 2015, PloS one.

Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy

J. Chien, T. Garay, D. Oien, 2018, Front. Pharmacol..

Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis

S. Spiegl-Kreinecker, D. Lötsch, C. Pirker, 2013, Oncotarget.

FGF2 and EGF induce epithelial–mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal

C. Pirker, T. Mohr, W. Berger, 2018, Carcinogenesis.

Deconstructing Immune Cell Infiltration in Human Colorectal Cancer: A Systematic Spatiotemporal Evaluation

B. Győrffy, B. Ács, M. Dank, 2022, Genes.

HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line

B. Döme, A. Bankfalvi, K. Schmid, 2020, Pathology & Oncology Research.

Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression

W. Berger, J. Tímár, M. Donia, 2019, International journal of molecular sciences.

Inhibition of EGFR improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model

J. Tímár, B. Hegedűs, J. Dobos, 2016 .

Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations

C. Pirker, W. Berger, J. Tímár, 2015, Pathology & Oncology Research.

Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients—A Single-Center Case-Control Study

M. Dank, T. Garay, Zoltán Herold, 2021, Diseases.

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells

W. Berger, B. Döme, J. Tímár, 2018, BMC Cancer.

Cell migration or cytokinesis and proliferation?--revisiting the "go or grow" hypothesis in cancer cells in vitro.

Walter Klepetko, Walter Berger, András Czirók, 2013, Experimental cell research.

RIG-I inhibits the MAPK-dependent proliferation of BRAF mutant melanoma cells via MKP-1.

A. Bácsi, B. Hegedűs, A. Szabo, 2016, Cellular signalling.

Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model

J. Tímár, B. Hegedűs, J. Dobos, 2018, Melanoma research.

Apelin promotes lymphangiogenesis and lymph node metastasis

W. Berger, W. Klepetko, M. Grusch, 2014, Oncotarget.

The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells

W. Berger, B. Döme, Rita Padányi, 2017, International journal of cancer.

Development and In Vivo Application of a Water-Soluble Anticancer Copper Ionophore System Using a Temperature-Sensitive Liposome Formulation

G. Szakács, J. Mihály, R. Bergmann, 2020, Pharmaceutics.

Next Generation Lipophilic Bisphosphonate Shows Antitumor Effect in Colorectal Cancer In Vitro and In Vivo

J. Tímár, S. Shirasawa, M. Dank, 2020, Pathology & Oncology Research.

Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells

B. Ghanim, W. Berger, W. Klepetko, 2012, British Journal of Cancer.

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells

W. Berger, B. Döme, J. Tímár, 2018, BMC Cancer.

Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations

J. Tímár, B. Hegedűs, C. Aigner, 2020, International journal of molecular sciences.